PMID- 14551706
OWN - NLM
STAT- MEDLINE
DCOM- 20040206
LR  - 20171116
IS  - 0723-5003 (Print)
IS  - 0723-5003 (Linking)
VI  - 98
IP  - 9
DP  - 2003 Sep 15
TI  - [Treatment of thrombosis with low-molecular-weight heparin. Comparison of body 
      weight-adjusted and fixed dosage].
PG  - 493-8
AB  - BACKGROUND: The treatment of deep vein thrombosis (DVT) has been simplified and 
      become safer after introduction of low-molecular-weight heparin (LMWH). The 
      dosage of LMWH was performed by body weight adjustment without dose-finding 
      studies. DATA: In three large clinical trials, the improved efficacy and safety 
      of body weight-independent fixed-dose LMWH Certoparin were demonstrated using 2 x 
      8,000 IU subcutaneously per day for the initial treatment of symptomatic acute 
      DVT. The reduction of thrombus size after 14 days, determined with the Marder 
      score, and the combined endpoint, consisting of recurrent thromboembolism, major 
      bleeding and mortality, was lower over the initial treatment with LMWH compared 
      to intravenous APTT-adjusted unfractionated heparin (UFH). The benefit of the 
      clinical endpoints over 6 months was demonstrated in two clinical trials. 
      CONCLUSION: Treatment of acute DVT is more effective and safer using fixeddose 2 
      x 8,000 IU Certoparin for the initial treatment compared to UFH.
FAU - Harenberg, Job
AU  - Harenberg J
AD  - IV. Medizinische Klinik, Universitatsklinikum Mannheim, Mannheim. 
      J-Harenberg@t-online.de
LA  - ger
PT  - Comparative Study
PT  - Journal Article
PT  - Review
TT  - Thrombosetherapie mit niedermolekularem HeparinVergleich von 
      korpergewichtsadjustierter mit fixer Dosierung.
PL  - Germany
TA  - Med Klin (Munich)
JT  - Medizinische Klinik (Munich, Germany : 1983)
JID - 8303501
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - V72OT3K19I (certoparin)
SB  - IM
EIN - Med Klin (Munich). 2004 Jan 15;99(1):42
MH  - Adult
MH  - Aged
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Data Interpretation, Statistical
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Phlebography
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Risk
MH  - Thromboembolism/diagnosis/etiology
MH  - Thrombophlebitis/complications/diagnostic imaging/*drug therapy/mortality
MH  - Time Factors
MH  - Treatment Outcome
RF  - 21
EDAT- 2003/10/11 05:00
MHDA- 2004/02/10 05:00
CRDT- 2003/10/11 05:00
PHST- 2003/03/31 00:00 [received]
PHST- 2003/07/02 00:00 [accepted]
PHST- 2003/10/11 05:00 [pubmed]
PHST- 2004/02/10 05:00 [medline]
PHST- 2003/10/11 05:00 [entrez]
AID - 10.1007/s00063-003-1290-9 [doi]
PST - ppublish
SO  - Med Klin (Munich). 2003 Sep 15;98(9):493-8. doi: 10.1007/s00063-003-1290-9.